Vyant Bio (NASDAQ:VYNT) Upgraded to Hold at Zacks Investment Research

Vyant Bio (NASDAQ:VYNT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel […]

Related Keywords

Vyant Bio ,Northern Trust Corp ,Geode Capital Management ,Zacks Investment Research ,Vyant Bio Company Profile Get Rating ,Renaissance Technologies ,Cancer Genetics Inc ,Charles Schwab Investment Management Inc ,Vyant Bio Inc ,Get Rating ,Street Corp ,Capital Management ,Schwab Investment Management ,Trust Corp ,Sbio Company Profile ,Nasdaq Vynt ,Vynt ,Medical ,Upgrade ,